Barclays launches U.S. biopharma coverage with four preferred picks
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/14/2026
- S&P 500 ends higher as strong inflation data cements rate-hike bets
- Oracle raises full year profit guidance, stock rises after hours
- Oil falls but head for 8% weekly gain on tight supply; US diesel hits record
- 'No panic anywhere' may be the problem, BofA strategists warn
- Buy Shopify stock at this ’AI-enabled entry point,’ analyst says
- S&P 500 ends higher as strong inflation data cements rate-hike bets
- Goldman Sachs tech conference highlights AI spending outlook
- Dell shares surge on record AI server bookings
- Buy Shopify stock at this ’AI-enabled entry point,’ analyst says
- 'No panic anywhere' may be the problem, BofA strategists warn
- After-Hours Movers: ORCL, CRWV, ADBE, ACVA, CPRT, ZUMZ, PMTS, RH
- After-Hours Movers: COO, AEO, NAVN, AVAV, TORO
- After-Hours Movers: LULU, IOT, PATH, DOCU, ASAN, GWRE, ZS, PL, SWBI, OXM
- After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE
- After-Hours Movers: DELL, PANW, GTLB, CRDO, MDB, HPE, SMCI
BofA on Eli Lilly (LLY): 'Novo’s GLP-1 price update unlikely to ‘rock the boat’'
February 24, 2026 10:11 AM ESTBofA Securities analyst Tim Anderson reiterated a Buy rating and $1,293.00 price target on Eli Lilly (NYSE: LLY).
The analyst comments "Todays announcement that Novo Nordisk (covered by Sachin Jain) plans to slash GLP-1 list prices offers a flashy headline, but in our view the update is unlikely to have any material impact on the US market. The price announcement is relevant only to commercial insurance channel (est. 30% of 25... More
Novo To Cut Ozempic, Wegovy's US List Prices By Up To 50% - WSJ
February 24, 2026 7:41 AM ESTNovo To Cut Ozempic, Wegovy's US List Prices By Up To 50% - WSJ
"Under the changes, both Ozempic and Wegovy will list for $675 a month, effective Jan. 1, 2027. That is half of the current price tag for anti-obesity therapy Wegovy and a 34% cut for diabetes treatment Ozempic. The... More